Biohit helps China quit smoking
Biohit and Chinese Chinmax Medical Systems have confirmed an agreement for the distribution of the Acetium lozenge in China.
The companies signed the contract for a preliminary period of seven years, containing a letter of intent for a joint venture arrangement and local production.
“Our new partner co-operates with more than 3 000 hospitals, smoking cessation clinics and respiratory disease clinics,” says Semi Korpela, CEO. “The product registration process has been started.”
Biohit is a globally operating Finnish biotechnology company that produces advanced services and solutions for health sector research and early diagnosis.
In a clinical trial, their product Acetium lozenge has been found to be effective in smoking cessation. It can be used to bind carcinogenic acetaldehyde in saliva to a harmless compound during smoking and to promote oral health.